Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer

Oncology (Switzerland)

Volumn 83, Issue 2, 2012, Pages 57-66

  Lim, Kyu Hyoung ^a,c   Han, Sae Won ^a,b   Oh, Do Youn ^a,b   Im, Seock Ah ^a,b   Kim, Tae You ^a,b   Bang, Yung Jue ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Graduate School   (South Korea)

^c Kangwon National University   (South Korea)

Author keywords

5 Fluorouracil; Biliary tract cancer; Doxorubicin; Mitomycin C; Prognostic factors

Indexed keywords

ANTIBIOTIC AGENT; DOXORUBICIN; FLUOROURACIL; MITOMYCIN C;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BILIARY TRACT CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY DYSFUNCTION; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MITOMYCIN; MULTIVARIATE ANALYSIS; NEUTROPENIA; PROGNOSIS; SERUM ALBUMIN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84863087085     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000338795     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Shin HR, Jung KW, Won YJ, Park JG; 139 KCCR-affiliated Hospitals: 2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat 2004; 36: 103-114.
3. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BSJ, Youssef BAM, Klimstra D, Blumgart LH: Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234: 507-517.
4. Glimelius B, Hoffman K, Sjödén PO, Jacobsson G, Sellström H, Enander LK, Linné T, Svensson C: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600. (Pubitemid 26285639)
5. Berardi R, Scartozzi M, Freddari F, Squadroni M, Santinelli A, Bearzi I, Fabris G, Cascinu S: Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review. Cancer Treat Rev 2006; 32: 333-347.
6. Hezel AF, Zhu AX: Systemic therapy for biliary tract cancers. Oncologist 2008; 13: 415-423. (Pubitemid 351679921)
7. Falkson G, MacIntyre JM, Moertel CG: Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984; 54: 965-969. (Pubitemid 14069807)
8. Ducreux M, Rougier P, Fandi A, Clavero- Fabri MC, Villing AL, Fassone F, Fandi L, Zarba J, Armand JP: Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 1998; 9: 653-656. (Pubitemid 28318199)
9. Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK: Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother Pharmacol 2007; 60: 321-328. (Pubitemid 46944586)
10. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C: Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 2004; 91: 1769-1774. (Pubitemid 39664963)
11. Kim YJ, Im SA, Kim HG, Oh SY, Lee KW, Choi IS, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Kim SW, Heo DS, Yoon YB, Bang YJ: A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. Ann Oncol 2008; 19: 99-103.
12. Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA, Tschetter LK: Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 2005; 103: 111-118. (Pubitemid 39665463)
13. Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, Heo JS, Park YS, Kang WK, Park K: A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 2006; 106: 1339-1346. (Pubitemid 43363912)
14. Riechelmann RP, Townsley CA, Chin SN, Pond GR, Knox JJ: Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 2007; 110: 1307-1312. (Pubitemid 47435603)
15. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators: cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281.
16. Oh SY, Jeong CY, Hong SC, Kim TH, Ha CY, Kim HJ, Lee GW, Hwang IG, Jang JS, Kwon HC, Kang JH: Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs 2011; 29: 1066-1072.
17. Lee S, Oh SY, Kim BG, Kwon HC, Kim SH, Rho MH, Kim YH, Rho MS, Jeong JS, Kim HJ: Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine- pretreated pancreatic and biliary tract cancer. Am J Clin Oncol 2009; 32: 348-352.
18. Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Ito Y, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K: Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 2012; 30: 708-713.
19. Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M, Koike K: Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Invest New Drugs 2011; 29: 1488-1493.
20. MacDonald JS, Woolley PV, Smythe T, Ueno W, Hoth D, Schein PS: 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 1979; 44: 42-47. (Pubitemid 9234907)
21. Smith FP, Hoth DF, Levin B, Karlin DA, MacDonald JS, Woolley PV 3rd, Schein PS: 5-Fluorouracil, adriamycin, and mitomycin- C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 1980; 46: 2014-2018. (Pubitemid 10025478)
22. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta- Analysis Group in Cancer. J Clin Oncol 1998; 16: 301-308.
23. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. Meta- Analysis Group in Cancer. J Clin Oncol 1998; 16: 3537-3541.
24. Eckel F, Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96: 896-902. (Pubitemid 46452283)
25. Crooke ST, Bradner WT: Mitoycin C: a review. Cancer Treat Rev 1976; 3: 121-139.
26. Taal BG, Audisio RA, Bleiberg H, Blijham GH, Neijt JP, Veenhof CH, Duez N, Sahmoud T: Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Oncol 1993; 4: 607-609. (Pubitemid 23257561)
27. Sartorelli AC, Boothe BA: The synergistic anti-neoplastic activity of combinations of mitomycins with either 6-thioguanine or 5-fluorouracil. Cancer Res 1965; 25: 1393-1400.
28. Kornek GV, Schuell B, Laengle F, Gruenberger T, Penz M, Karall K, Depisch D, Lang F, Scheithauer W: Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol 2004; 15: 478-483. (Pubitemid 38444553)
29. Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, Ross PJ, Oates J, Norman AR: Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005; 92: 1650-1654. (Pubitemid 40756474)
30. Suzuki E, Furuse J, Ikeda M, Okusaka T, Nakachi K, Mitsunaga S, Ueno H, Morizane C, Kondo S, Shimizu S, Kojima Y, Hagihara A: Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases. Oncology 2010; 79: 39-45.
31. Park I, Lee JL, Ryu MH, Kim TW, Sook Lee S, Hyun Park D, Soo Lee S, Wan Seo D, Koo Lee S, Kim MH: Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving firstline palliative chemotherapy. Cancer 2009; 115: 4148-4155.
32. Sasaki T, Isayama H, Nakai Y, Togawa O, Kogure H, Ito Y, Yamamoto K, Mizuno S, Yagioka H, Yashima Y, Kawakubo K, Arizumi T, Matsubara S, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K: Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. Cancer Chemother Pharmacol 2011; 67: 847-853.
33. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ: Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005; 23: 2332-2338. (Pubitemid 46218726)
34. André T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A, Louvet C; GERCOR Group: Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15: 1339-1343. (Pubitemid 39295020)